



De.mem Limited (ASX:DEM)

Investor Presentation

Strategic Shift to Recurring Revenues Underpins Strong FY20 Outlook

2 March 2020



For personal use only

CONTENTS

RESULTS OVERVIEW

- 3 BUSINESS OVERVIEW
- 4 CORPORATE SNAPSHOT
- 5 FY19 KEY MILESTONES
- 6 FY19 MILESTONE PROJECTS
- 7 FY19 FINANCIAL SUMMARY
- 8 GROWING RECURRING REVENUES
- 11 FY20 OUTLOOK

KEY INVESTMENT CONSIDERATIONS

- 12 KEY INVESTMENT CONSIDERATIONS
- 13 RELATIVE VALUATION DISCOUNT
- 14 BLUE CHIP CUSTOMER BASE
- 15 UNIQUE TECHNOLOGY PORTFOLIO
- 16 STRONG CUSTOMER VALUE PROPOSITION



De.mem is a “one-stop shop” provider of industrial water treatment solutions.

DEM combines its unique water treatment technology product portfolio with repeat sales of water treatment consumables (pumps, filters, membranes, chemicals) and its specialist water engineering & design skills.



What we do

De.mem designs, builds, operates, owns and services water treatment systems for de-centralized applications based on proprietary membrane technology.



Key Product Lines

- Water treatment equipment – membrane-based, chemical, biological
- Water treatment services - Build, Own, Operate (BOO), Operations & Maintenance (O&M)
- Water treatment chemicals - flocculants & coagulants, membrane cleaners, anti-scalants etc.
- Other consumables - membranes, filters, pumps, other



Key Target Markets

All major water treatment applications: Potable, sewage, industrial waste and process water. Key target growth segments: Food & Beverage, Agriculture.

The global market for packaged / decentralised water treatment systems was valued at USD 12 billion in 2015 and is projected to reach USD 21.8 billion by 2021 - a compounded growth of 10.4% per annum (Markets & Markets)



Locations

Brisbane, Adelaide, Melbourne, Perth, Singapore, Ho Chi Minh City / Vietnam, Essen, Essen / Germany



Employees

60 in total comprising - 45 Australia, 9 Singapore, 6 Germany



● Offices

○ Projects Completed

For personal use only

For personal use only

MARKET DATA


ASX code	DEM
Ordinary shares	175.4m
Market capitalisation	\$30m
Cash on hand (31.12.19)	\$8.2m
Listed on ASX	7 April 2017
Issue price	\$0.20
Last price (28.02.20)	\$0.17
52 week high	\$0.36
52 week low	\$0.09
Average daily volume	~252,000
GICS classification	Utilities

MAJOR SHAREHOLDERS


NA Singapore Early-Stage Venture Fund	24.0%
Perennial Value Microcap Opportunities Fund	14.2%
New Asia Investments Pte Ltd	6.8%
Mr Andreas Hendrik De Wit	5.5%
Pathfinder Fund	2.9%
Mr. Andreas Kroell	1.6%

SHARE PRICE PERFORMANCE

DEM Stock Price



DEM Relative to ASX Small Industrials



In FY19, DEM accelerated its transition to a recurring revenue business which provides a “complete one stop shop” for industrial water treatment solutions. DEM commences FY20F with visible revenues exceeding FY19 revenues.



“One-stop shop” supplier of decentralised industrial water treatment solutions – Supplies wide range of water treatment equipment including proprietary membrane technology, services, chemicals and consumables (pumps, filters, membranes)



Developed strong recurring revenue base for FY20 – Approx. \$10m recurring revenue base for FY20F comprising a mix of Build, Own, Operate (equipment leasing); Operations & Maintenance; chemicals; consumables sales (pumps, filters, membranes).



Maintains visible path to cash positive – Operating cash outflow reduced, record H2 CY 2020 customer cash receipts of ~\$6.7m (\$3.3m December quarter 2019 and \$3.4m September quarter 2019) corresponding to total annualized ~\$13.4m customer cash receipts




Strong balance sheet – \$8.2m cash as at 31 December 2019; company appears well-funded to achieve operating cash positive and grow Build, Own, Operate (equipment leasing) segment



Acquisition integration – Completed acquisition of Pumptech (expanded the business into Tasmania and food & beverage segment) and Geutec (expanded the business into Germany and water treatment chemicals supply)

Breakthrough Project Awards in FY19 – providing a strong foundation for follow-on work

- Client is **Mulpha**, an international infrastructure investor with a number of assets in Australia
- Total value of project is approx. A\$3m
- Desalination plant based on a Sea Water Reverse Osmosis Process deploying innovative membrane technology
- Provides potable water to a luxury resort in Australia
- Completed by De.mem in 2019
- Strong reference for further work in hospitality / hotels & resorts sector and for technical excellence in desalination



- Client is **Givaudan**, worldwide leader in the creation of flavours & fragrances
- Build, Own, Operate project with a total value of approx. A\$1.7m over the initial term
- Industrial waste water treatment system integrating multiple treatment processes – using De.mem hollow fibre membranes as key treatment step
- Treats the waste water from a factory in Singapore to legal discharge standards
- Awarded to De.mem in November 2019 and currently under execution
- Strong reference for food & beverage clients

DEM increased cash receipts by 15% to \$11.7m in CY2019

DEM is growing its recurring revenue base and has a visible path to sustainable operating cash positive
 At the current market capitalisation, it is trading at 1.3 x market cap / paid-in equity

A\$m (Dec yr end)	2016	2017	2018	2019
Cash receipts	0.8	2.6	10.2	11.7
Total income	0.3	3.0	10.6	10.8
COGS	0.4	2.4	7.9	7.5
Operating Profit	(-0.1)	0.6	2.7	3.3
Operating Margin (% of revenues)	Neg.	19%	25%	29%
Net Operating Cash Flows	(-1.2)	(-2.4)	(-1.6)	(-1.7)

HIGH AND GROWING OPERATING MARGIN

- From 19% in CY17 to 25% in CY18 to 29% in FY19
- High margin business relative to industry average

REPLACEMENT VALUE

Approx. \$24m replacement value, comprising:

- Cash balance \$8.2m as at 31 Dec 2019
- Total expenses since inception of approx. \$16m

STRONG CASHFLOWS

- Strong H2 operating cashflow momentum, with record H2 CY 2019 cash inflows of ~\$6.7m (\$3.3m Dec and \$3.4m in Sept quarter), for \$13.4m annualised
- Visible path to cash positive CY 18 operating cash outflow of \$1.6m reduced to \$1.1m in CY19 (adjusted for delayed customer payments – see Dec Quarter 2019 ASX release)

REVENUE GROWTH

- High revenue growth from \$10.6m 2018 to \$10.8m in FY19 (excluding FY19 contracted revenues carried over into FY20 of \$1.4m). Including \$1.4m FY19 carried over revenues, adjusted FY19 revenue would be \$12.2m, or growth of 15% vs FY18
- Growing recurring revenue from \$4.0m in FY18 to \$6.0m in FY19, with visible recurring revenues of \$10m in FY20F
- Improving revenue quality with growing recurring revenues and revenue diversification

CASH BALANCE

- Strong cash (including term deposits) balance \$8.2m as at 31 Dec 2019

Recurring revenues include BOO, O&M and Consumables Sales. Recurring revenues are increasing from 38% of total revenue in FY18 to 56% in FY19, with FY20 outlook for continued growth in recurring revenues.



Equipment Sales

- Sale of water and waste water treatment systems
- Providing a turn key solution to the customer
- Typically projects-based, with strong and stable repeat customer base



Build-Own-Operate or Build-Own-Transfer

- De.mem owns and rents out the equipment
- Long term contract with the customer
- Stable and recurring revenue stream
- High margin



Operations and Maintenance

- De.mem operates & maintains water treatment equipment owned by the client
- Long-term or revolving contract
- Stable and recurring revenue stream



Consumables Sales

- Includes the sale of
 - Chemicals
 - Filters
 - Membrane modules
 - Pumps
 - Other spare parts
- Stable and recurring revenue stream

EQUIPMENT SALES:

~62% of revenues (2018)
~44% of revenues (2019)

BOO & O&M:

~33% of revenues (2018)
~30% of revenues (2019)

CONSUMABLES SALES:

~5% of revenues (2018)
~26% of revenues (2019)

Recurring revenues are growing, from 38% of total revenue in FY18 to 56% in FY19. The outlook is for continued growth in recurring revenues, supporting FY20F total cash receipts/revenue guidance of \$16-20m.


- Recurring revenue increased from 38% of FY18 revenues to 56% of FY19
- Recurring revenue expected to generate an increasing % of total revenues in FY20

A\$M	% FY18A	FY18A	% FY19A	FY19A	FY20F
Subtotal - recurring revenue					
Recurring revenue (% total revenue)	38%	4.0	56%	6.0	10
FY19 contracted revenue					1.4
Subtotal - Equipment sales	62%	6.6	44%	4.8	TBD
Total Revenue	100%	10.6	100%	10.8	16-20

FY20F has a minimum visible revenue base of \$11.4m, with equipment sales to further add to FY20F total revenue.

FY20F recurring revenue base is approx. \$10m with an additional \$1.4m contracted revenue carried over from FY19.

For context, equipment sales have historically ranged from \$5.2m (FY18) to \$6.6m to (FY19), though the business has grown since then.



For personal use only



Ongoing top line growth

- FY20F cash receipts/revenue guidance of \$16-\$20m, driven by \$10m of recurring revenues and \$1.4m FY19 contract rollover
- Visible path to sustainable operating cash positive with diminishing operating cash outflow



Contracts

Strong customer pipeline with ongoing new contract wins expected



Expansion into new geographies

Regional growth from strong client base in Queensland into South East and Western Australia, as well as internationally with a focus on the Asia Pacific region



Cross-sell

De.mem, Geutec and Pumpteck cross-sell is a key FY20 focus



Product enhancement

Access to new technology / expansion of intellectual property portfolio

For personal use only



Projects Completed

Uniquely positioned to become the leading player in decentralized water treatment across APAC, providing a range of proven, world-class, highly scalable and potentially disruptive technologies to a large addressable market




Proprietary technology – De.mem has access to a range of proven, disruptive, easy-to-scale membrane technologies targeting a huge addressable market. Part of the IP is owned by De.mem, other has been licensed exclusively from Nanyang Technological University (NTU), Singapore – ranked no. 2 in membrane research worldwide by Lux Research (2013).



High growth market – The global water industry is estimated to reach US\$915bn by 2023 (source: *Global Water Intelligence*). The global market for packaged / decentralised water treatment systems was valued at USD 12 bn in 2015 and is projected to reach USD 21.8 billion by 2021 - a compounded growth of 10.4% per annum (source: *Markets & Markets*).



Blue chip customer base – Including: Rio Tinto, Monadelphous, Bechtel, Civeo, Ausco (mining/resources); St Hilliers, Mulpha, Acciona, JRK Group, Taswater (infrastructure/municipal); Givaudan (F&B), FMC Technip (industrial), with many repeat orders.



High top line growth – cash receipts from \$0.8m in 2016 to \$2.6m in 2017 to \$10.2m 2018 and \$11.7m in CY19 (unadjusted for customer payments of \$0.9m delayed into CY 2020). CY20F guidance of \$16-20m cash receipts/revenue, which is within the range of achieving sustainable operating cash positive.



Growing recurring revenues – Recurring revenues have increased from 38% of total revenue in FY18 to 56% in FY19, with guidance of \$10m recurring revenue base in FY20F (in addition to non-recurring equipment sales revenue)



Multiple growth drivers – high growth addressable market; growing product range; emerging new technologies; cross-sell opportunities; recent expansion into new geographies (Western Australia and Pacific Islands).



Visible path to cash positive – Net cash used in operating activities of \$1.6m in CY18 reduced to \$1.1m in CY19 (adjusted for delayed customer payments – see Dec Quarter 2019 ASX release). Reduced operating cash outflows in every single quarter relative to prior year period. Flexible revenue model, low cost base, services/consumables sales provide stable recurring revenues.



Valuation discounts

- DEM trades at 2.6x Market Capitalisation/Revenue (x) multiple, which is ~75% discount to its ASX-listed peer average
- Current market cap is close to replacement value of ~A\$24m (comprising \$8.2m cash and \$16m expenses incurred to date, not including the cost of Nanyang Technological University R&D spend on membrane technology)

DEM trades at 2.6x Market Capitalisation/Revenue (x) multiple, which is ~75% discount to its ASX-listed peer average

Company	Last 12 Months Customer Cash Receipts	Market Capitalisation (28 February 2020)	Market Capitalisation / Revenue	Technology	Market Focus
Phoslock Water Solutions ASX: PET	A\$28.1m 12 months to 31/12/19	A\$325m	11.5x	Chemicals to bind phosphorus	Prevention of algae growth
Fluence ASX: FLC	A\$93.2m 12 months to 31/12/19	A\$194m	2.1x	Aerobic waste water treatment (MABR)	Municipal waste water
Puriflo ASX: PO3	A\$0.0m 12 months to 31/12/19	A\$79m	NA	Free Radical Generation (FRG)	Water treatment, air, surface sterilisation
Scidev ASX: SDV	A\$5.4m 12 months to 31/12/19	A\$84m	15.8x	Chemicals	Coagulants and flocculants for wastewater treatment and sludge dewatering
Average			9.9x		
De.mem ASX: DEM	A\$11.7m 12 mths - FY19 (Dec year end)	A\$30m	2.6x	Membranes	Industrial water treatment solutions

For personal use only

DEM has large, blue-chip clients that often provide repeat orders across their global operations. Customers include global mining companies, large EPC contractors, municipalities, water utilities and multinational corporations

Mining	Municipal / Infrastructure	Food & Beverage	Other Industrial
<ul style="list-style-type: none"> • Potable/sewage treatment for mining camps • Waste water • Supply of water for mine operations 	<ul style="list-style-type: none"> • Potable • Municipal sewage 	<ul style="list-style-type: none"> • Key 2020 growth sector • Waste water • Process water • Recycling 	<ul style="list-style-type: none"> • Industrial waste water • Process water • Recycling

For personal use only

De.mem proprietary product portfolio includes breakthrough membrane innovations

COMPLETED (2018 and 2019)

- **Nanofiltration membrane**
 - Superior filtration performance due to minimum pore size at low pressure / energy consumption
 - In-house developed and fully owned by De.mem
- **Ultrafiltration membrane**
 - Large applicable market, i.e. pre-filtration for Reverse Osmosis and potable water treatment
 - In-house developed and fully owned by De.mem
- **Forward Osmosis membrane**
 - De-watering of industrial waste water and liquid concentration in F&B (via Aromatec Pte Ltd)
 - Developed at and licensed from NTU
- **Microfiltration membrane**
 - Large applicable market, including process water applications in F&B; in-house development
- **Domestic “point of use” filter system**

PLANNED (2020 FF)

- **Membrane Bioreactor (MBR)**
 - Treatment of high organic load waste water
- **New membrane technologies**
 - Using new materials



For personal use only

**De.mem as a Total Water Management Solutions Provider:
A “One-stop-shop” for the customer**

- De.mem supplies all major types of water and waste water treatment equipment
- Proven service (Operations & Maintenance) and after-sales capability and ability to supply all consumables required by the customer for the ongoing operations of the plant
- Unique Build, Own, Operate offering
- Deep technical know-how based on long term experience and strong team
- Access to proprietary products/components, deployed as part of the systems to provide a “competitive edge”
- Partnership in R&D with Nanyang Technological University, Singapore
- Strong know-how in automation and de.live remote monitoring platform
- Highest quality standards ensured through industry qualifications i.e. ISO 9001:2015
- “Made in Australia” products for Australian customers



This presentation has been prepared by De.mem Limited and its related entities (the "Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation. This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so). Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future Matters | This presentation contains reference to certain intentions, expectations, future plans, strategy, revenue forecasts and prospects of the Company. Those intentions, expectations, future plans, strategy, revenue forecasts and prospects may or may not be achieved and may be forward looking statements. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy, revenue forecasts and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure | This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). The Company's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

All figures included in this presentation are in AUD\$ unless otherwise stated. Assumed exchange rate of AUD\$1:USD\$0.65



DE.MEM LIMITED (ASX:DEM)

Andreas Kroell

Chief Executive Officer

De.mem Limited

investor@demem.com.sg

INVESTOR ENQUIRIES

George Gabriel, CFA

Managing Director

BLETCHLEY Park Capital

investors@bletchleyparkcapital.com.au

(03) 8686 9144

For personal use